Patents Assigned to Genfit
  • Pharmaceutical compositions for combination therapy
    Patent number: 11191749
    Abstract: The present invention relates to a combination product and its use in therapy.
    Type: Grant
    Filed: March 13, 2018
    Date of Patent: December 7, 2021
    Assignee: GENFIT
    Inventors: Dean Hum, Robert Walczak, Carole Belanger, Corinne Foucart
  • Methods of treatment of cholestatic diseases
    Patent number: 11185519
    Abstract: The present invention relates to the use of compound 1-[4-methylthiophenyl]-3-[3,5-dimethyl-4-carboxydimethyl-methyloxyphenyl]prop-2-en-1-one (Elafibranor or GFT505) for treating cholestatic diseases, and more specifically PBC and/or PSC.
    Type: Grant
    Filed: March 30, 2017
    Date of Patent: November 30, 2021
    Assignee: Genfit
    Inventor: Rémy Hanf
  • RORgamma modulators and uses thereof
    Patent number: 11160801
    Abstract: The present invention provides novel compounds that are modulators of RORgamma. These compounds, and pharmaceutical compositions comprising the same, are suitable means for treating any disease wherein the modulation of RORgamma has therapeutic effects, for instance in autoimmune diseases, autoimmune-related diseases, inflammatory diseases, metabolic diseases, fibrotic diseases, or cholestatic diseases.
    Type: Grant
    Filed: January 29, 2018
    Date of Patent: November 2, 2021
    Assignee: Genfit
    Inventors: Jean-Francois Delhomel, Enrico Perspicace, Zouher Majd, Peggy Parroche, Robert Walczak, Pascal Bonnet, Jade Fogha
  • Methods of treatment for cholestatic and fibrotic diseases
    Patent number: 11103484
    Abstract: The present invention relates to the compound [2-[(5-nitro-1,3-thiazol-2-yl)carbamoyl]phenyl]ethanoate (Nitazoxanide) or 2-hydroxy-N-(5-nitro-2-thiazolyl)benzamide (Tizoxanide) for treating cholestatic and fibrotic diseases.
    Type: Grant
    Filed: June 24, 2020
    Date of Patent: August 31, 2021
    Assignee: Genfit
    Inventors: Raphael Darteil, Robert Walczak, Carole Belanger, Emilie Negro, Pierre Daubersies, Philippe Delataille
  • Rorgamma modulators and uses thereof
    Patent number: 11077115
    Abstract: The present invention provides novel compounds of formula (Ia) that are modulators of RORgamma. These compounds, and pharmaceutical compositions comprising the same, are suitable means for treating any disease wherein the modulation of RORgamma has therapeutic effects, for instance in autoimmune diseases, autoimmune-related diseases, inflammatory diseases, metabolic diseases, fibrotic diseases, or cholestatic diseases.
    Type: Grant
    Filed: January 29, 2018
    Date of Patent: August 3, 2021
    Assignee: Genfit
    Inventors: Jean-Francois Delhomel, Enrico Perspicace, Zouher Majd, Peggy Parroche, Robert Walczak, Pascal Bonnet, Jade Fogha
  • N-{[2-(piperidin-1-yl)phenyl](phenyl)methyl}-2-(3-oxo-3,4-dihydro-2H-1,4-benzoxazin-7-yl)acetamide derivatives and related compounds as ROR-gamma modulators for treating autoimmune diseases
    Patent number: 11052092
    Abstract: The present invention provides e.g. N-{[2-(piperidin-1-yl)phenyl](phenyl)methyl}-2-(3-oxo-3,4-dihydro-2H-1,4-benzoxazin-7-yl)acetamide derivatives and related compounds as ROR-gamma modulators for treating e.g. autoimmune diseases, autoimmune-related diseases, inflammatory diseases, metabolic diseases, fibrotic diseases or cholestatic diseases, such as e.g. arthitis and asthma.
    Type: Grant
    Filed: January 29, 2018
    Date of Patent: July 6, 2021
    Assignee: Genfit
    Inventors: Jean-Francois Delhomel, Enrico Perspicace, Zouher Majd, Peggy Parroche, Robert Walczak
  • Pharmaceutical compositions for combination therapy
    Patent number: 11033534
    Abstract: The present invention relates to a combination product and its use in therapy.
    Type: Grant
    Filed: January 29, 2018
    Date of Patent: June 15, 2021
    Assignee: GENFIT
    Inventors: Corinne Foucart, Robert Walczak, Carole Belanger, Benoït Noel
  • RORgamma modulators and uses thereof
    Patent number: 10987351
    Abstract: The present invention provides novel compounds of formula (Ia) that are modulators of RORgamma. These compounds, and pharmaceutical compositions comprising the same, are suitable means for treating any disease wherein the modulation of RORgamma has therapeutic effects, for instance in autoimmune diseases, autoimmune-related diseases, inflammatory diseases, metabolic diseases, fibrotic diseases, or cholestatic diseases.
    Type: Grant
    Filed: January 29, 2018
    Date of Patent: April 27, 2021
    Assignee: Genfit
    Inventors: Jean-Francois Delhomel, Enrico Perspicace, Zouher Majd, Peggy Parroche, Robert Walczak, Pascal Bonnet, Jade Fogha
  • Methods of treatment for cholestatic and fibrotic diseases
    Patent number: 10905680
    Abstract: The present invention relates to the compound [2-[(5-nitro-1,3-thiazol-2-yl)carbamoyl]phenyl]ethanoate (Nitazoxanide) or 2-hydroxy-N-(5-nitro-2-thiazolyl)benzamide (Tizoxanide) for treating cholestatic and fibrotic diseases.
    Type: Grant
    Filed: December 4, 2018
    Date of Patent: February 2, 2021
    Assignee: GENFIT
    Inventors: Raphael Darteil, Robert Walczak, Carole Belanger, Emilie Negro, Pierre Daubersies, Philippe Delataille
  • Derivatives of 6-substituted triazolopyridazines as Rev-Erb agonists
    Patent number: 10799510
    Abstract: The present invention provides novel 6-substituted [1,2,4]triazolo[4,3-b]pyridazines that are agonists of Rev-Erb. These compounds, and pharmaceutical compositions comprising the same, are suitable means for treating any disease wherein the activation of Rev-Erb has therapeutic effects, for instance in inflammatory and circadian rhythm-related disorders or cardiometabolic diseases.
    Type: Grant
    Filed: March 6, 2017
    Date of Patent: October 13, 2020
    Assignee: Genfit
    Inventors: Maryline Bourotte, Jean-Francois Delhomel, Mathieu Dubernet, Marie-Helene Gouy
  • Methods of treatment of fibrosis and cancers
    Patent number: 10792277
    Abstract: The present invention relates to the use of compound 1-[4-methylthiophenyl]-3-[3,5-dimethyl-4-carboxydimethyl-methyloxyphenyl]prop-2-en-1-one for treating fibrotic diseases and cancers.
    Type: Grant
    Filed: May 4, 2017
    Date of Patent: October 6, 2020
    Assignee: GENFIT
    Inventors: Rémy Hanf, Dean Hum, Robert Walczak, Benoît Noel
  • Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders
    Patent number: 10722575
    Abstract: The invention provides 1,3-diphenylprop-2-en-1-one derivatives and pharmaceutical compositions comprising the same for treating liver disorders, in particular those requiring the reduction of plasma level of biochemical markers such as aminotransferases. The 1,3-diphenylprop-2-en-1-one derivatives of General Formula (I) have hepatoprotective properties and can be used in methods for treating liver disorders involving the pathological disruption, inflammation, degeneration, and/or proliferation of liver cells, such as liver fibrosis or fatty liver disease.
    Type: Grant
    Filed: May 29, 2019
    Date of Patent: July 28, 2020
    Assignee: GENFIT
    Inventors: Raphael Darteil, Rémy Hanf, Dean Hum, Ingrid Dufour
  • NON-INVASIVE DIAGNOSTIC OF NON-ALCOHOLIC FATTY LIVER DISEASES, NON-ALCOHOLIC STEATOHEPATITIS AND/OR LIVER FIBROSIS
    Publication number: 20200216901
    Abstract: The present invention relates to a novel non-invasive method for the diagnosis of a non-alcoholic fatty liver disease, in particular non-alcoholic steatohepatitis, and/or liver fibrosis.
    Type: Application
    Filed: September 14, 2018
    Publication date: July 9, 2020
    Applicant: Genfit
    Inventors: Remy HANF, Genevieve CORDONNIER, John BROZEK
  • Methods of treatment for cholestatic and fibrotic diseases
    Patent number: 10653678
    Abstract: The present invention relates to synergistic combination of active ingredients for use in the treatment of fibrotic diseases.
    Type: Grant
    Filed: April 20, 2018
    Date of Patent: May 19, 2020
    Assignee: GENFIT
    Inventors: Robert Walczak, Corinne Foucart, Philippe Delataille
  • NON-INVASIVE DIAGNOSTIC OF NON-ALCOHOLIC STEATOHEPATITIS
    Publication number: 20190352715
    Abstract: The invention relates to a novel method for the diagnosis of non-alcoholic steatohepatitis (NASH), and for classifying a subject as a potential receiver of a treatment for NASH.
    Type: Application
    Filed: March 30, 2017
    Publication date: November 21, 2019
    Applicant: Genfit
    Inventors: Raphael Darteil, Geneviève Cordonnier, John Brozek, Emilie Praca, Fouad Ben Sudrik
  • Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders
    Patent number: 10350181
    Abstract: The invention provides 1,3-diphenylprop-2-en-1-one derivatives and pharmaceutical compositions comprising the same for treating liver disorders, in particular those requiring the reduction of plasma level of biochemical markers such as aminotransferases. The 1,3-diphenylprop-2-en-1-one derivatives of General Formula (I) have hepatoprotective properties and can be used in methods for treating liver disorders involving the pathological disruption, inflammation, degeneration, and/or proliferation of liver cells, such as liver fibrosis or fatty liver disease.
    Type: Grant
    Filed: June 13, 2018
    Date of Patent: July 16, 2019
    Assignee: GENFIT
    Inventors: Raphael Darteil, Rémy Hanf, Dean Hum, Ingrid Dufour
  • Methods of treatment for cholestatic and fibrotic diseases
    Patent number: 10130613
    Abstract: The present invention relates to the compound [2-[(5-nitro-1,3-thiazol-2-yl)carbamoyl]phenyl]ethanoate (Nitazoxanide) or 2-hydroxy-N-(5-nitro-2-thiazolyl)benzamide (Tizoxanide) for treating cholestatic and fibrotic diseases.
    Type: Grant
    Filed: December 14, 2017
    Date of Patent: November 20, 2018
    Assignee: Genfit
    Inventors: Raphael Darteil, Robert Walczak, Carole Belanger, Emilie Negro, Pierre Daubersies, Philippe Delataille
  • Methods of treatment for cholestatic and fibrotic diseases
    Patent number: 10130612
    Abstract: The present invention relates to the compound [2-[(5-nitro-1,3-thiazol-2-yl)carbamoyl]phenyl]ethanoate (Nitazoxanide) or 2-hydroxy-N-(5-nitro-2-thiazolyl)benzamide (Tizoxanide) for treating cholestatic and fibrotic diseases.
    Type: Grant
    Filed: December 11, 2017
    Date of Patent: November 20, 2018
    Assignee: Genfit
    Inventors: Raphael Darteil, Robert Walczak, Carole Belanger, Emilie Negro, Pierre Daubersies, Philippe Delataille
  • Methods of treatment for cholestatic and fibrotic diseases
    Patent number: 10117856
    Abstract: The present invention relates to the compound [2-[(5-nitro-1,3-thiazol-2-yl)carbamoyl]phenyl]ethanoate (Nitazoxanide) or 2-hydroxy-N-(5-nitro-2-thiazolyl)benzamide (Tizoxanide) for treating cholestatic and fibrotic diseases.
    Type: Grant
    Filed: December 14, 2017
    Date of Patent: November 6, 2018
    Assignee: Genfit
    Inventors: Raphael Darteil, Robert Walczak, Carole Belanger, Emilie Negro, Pierre Daubersies, Philippe Delataille
  • Methods of treatment for cholestatic and fibrotic diseases
    Patent number: 10117855
    Abstract: The present invention relates to the compound [2-[(5-nitro-1,3-thiazol-2-yl)carbamoyl]phenyl]ethanoate (Nitazoxanide) or 2-hydroxy-N-(5-nitro-2-thiazolyl)benzamide (Tizoxanide) for treating cholestatic and fibrotic diseases.
    Type: Grant
    Filed: December 14, 2017
    Date of Patent: November 6, 2018
    Assignee: Genfit
    Inventors: Raphael Darteil, Robert Walczak, Carole Belanger, Emilie Negro, Pierre Daubersies, Philippe Delataille